PTJ
OKUR

Paul Tudor Jones’s OnKure Therapeutics OKUR Stock Holding History

Paul Tudor Jones’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,341
Closed -$125K – 2868
2021
Q2 		$125K Buy
+1,341
New +$150K ﹤0.01% 1523

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paul Tudor Jones's OKUR Position: Q3 2021 in Review

Paul Tudor Jones sold out of OnKure Therapeutics (OKUR) in Q3 2021, closing a stake of 1,341 shares — an estimated $125K sold.

Paul Tudor Jones first reported a position in OKUR in Q2 2021 and held it in 1 quarter. The position peaked at $125K in Q2 2021. 38 funds tracked by Wall St. Rank hold OKUR as of Q3 2021.

  • Paul Tudor Jones reported no remaining OnKure Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 1,341 OnKure Therapeutics shares in Q3 2021, an estimated $125K.
  • Paul Tudor Jones first reported a position in OnKure Therapeutics in Q2 2021 and held it in 1 quarter.
  • Paul Tudor Jones's OnKure Therapeutics position peaked at $125K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.